Tags

Type your tag names separated by a space and hit enter

Cannabinoid system in neurodegeneration: new perspectives in Alzheimer's disease.
Mini Rev Med Chem. 2009 May; 9(5):539-59.MR

Abstract

Alzheimer's disease is a chronic and progressive neurodegenerative disorder. The presence of functional cannabinoid CB2 receptors in central nervous system (CNS) has provoked that this receptor and its agonist ligands are now considered as promising pharmacological targets for neurological diseases. Herein, we review the evidences supporting the potential role of the ECS as a therapeutic target, focused on CB2 receptor and its ligands, for the treatment of Alzheimer's disease.

Authors+Show Affiliations

Instituto de Q. Médica (CSIC). Juan de la Cierva, 3, 28006-Madrid, Spain. nuria@suricata.iqm.csic.esNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

19456285

Citation

Campillo, N E., and J A. Páez. "Cannabinoid System in Neurodegeneration: New Perspectives in Alzheimer's Disease." Mini Reviews in Medicinal Chemistry, vol. 9, no. 5, 2009, pp. 539-59.
Campillo NE, Páez JA. Cannabinoid system in neurodegeneration: new perspectives in Alzheimer's disease. Mini Rev Med Chem. 2009;9(5):539-59.
Campillo, N. E., & Páez, J. A. (2009). Cannabinoid system in neurodegeneration: new perspectives in Alzheimer's disease. Mini Reviews in Medicinal Chemistry, 9(5), 539-59.
Campillo NE, Páez JA. Cannabinoid System in Neurodegeneration: New Perspectives in Alzheimer's Disease. Mini Rev Med Chem. 2009;9(5):539-59. PubMed PMID: 19456285.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabinoid system in neurodegeneration: new perspectives in Alzheimer's disease. AU - Campillo,N E, AU - Páez,J A, PY - 2009/5/22/entrez PY - 2009/5/22/pubmed PY - 2009/7/9/medline SP - 539 EP - 59 JF - Mini reviews in medicinal chemistry JO - Mini Rev Med Chem VL - 9 IS - 5 N2 - Alzheimer's disease is a chronic and progressive neurodegenerative disorder. The presence of functional cannabinoid CB2 receptors in central nervous system (CNS) has provoked that this receptor and its agonist ligands are now considered as promising pharmacological targets for neurological diseases. Herein, we review the evidences supporting the potential role of the ECS as a therapeutic target, focused on CB2 receptor and its ligands, for the treatment of Alzheimer's disease. SN - 1389-5575 UR - https://www.unboundmedicine.com/medline/citation/19456285/Cannabinoid_system_in_neurodegeneration:_new_perspectives_in_Alzheimer's_disease_ L2 - http://www.eurekaselect.com/84312/article DB - PRIME DP - Unbound Medicine ER -